Sonoma Pharmaceuticals (SNOA) awards 10,000 stock options to board director Weigerstorfer

Rhea-AI Filing Summary

Sonoma Pharmaceuticals, Inc. director Philippe Weigerstorfer received a grant of stock options for 10,000 shares of common stock at an exercise price of $1.2600 per share. The options vest in three equal installments on July 9, 2027, July 9, 2028, and July 9, 2029, or upon a change of control. Following this award, he holds 30,001 stock options directly, expiring on July 9, 2036, as compensation for his Board service.

Insights

Equity compensation analyst

Director received routine stock option compensation, no open-market trading.

Director Philippe Weigerstorfer was granted stock options for 10,000 shares of Sonoma Pharmaceuticals common stock at an exercise price of $1.2600 per share. This is coded as a grant/award, not a market purchase or sale.

The options vest one-third annually on July 9, 2027, July 9, 2028, and July 9, 2029, or upon a change of control, aligning his incentives with longer-term company performance. After the grant, he directly holds 30,001 options expiring on July 9, 2036, indicating continued equity-based compensation rather than a change in ownership through trading.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Weigerstorfer Philippe

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	10,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 30,001 shares (Direct)

Footnotes (2)

1. F1. The options vest one third each on 7/9/2027, 7/9/2028 and 7/9/2029, or upon change of control.
2. F2. The options were awarded and granted to Mr. Weigerstorfer for services performed on the Board of Directors.

Key Figures

Options granted: 10,000 stock options Exercise price: $1.2600 per share Total options after grant: 30,001 stock options +2 more

5 metrics

Options granted 10,000 stock options Grant of stock options to director on July 9, 2026

Exercise price $1.2600 per share Exercise price of options granted to director

Total options after grant 30,001 stock options Director’s stock option holdings following the transaction

Expiration date July 9, 2036 Expiration of the granted stock options

Vesting schedule One third on 7/9/2027, 7/9/2028, 7/9/2029 Time-based vesting of the stock option grant

Key Terms

stock option, exercise price, change of control, vesting

4 terms

stock option financial

"The options were awarded and granted to Mr. Weigerstorfer"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price": "1.2600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

change of control financial

"or upon change of control."

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

vesting financial

"The options vest one third each on 7/9/2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What transaction did Sonoma Pharmaceuticals (SNOA) report for Philippe Weigerstorfer?

Sonoma Pharmaceuticals reported that director Philippe Weigerstorfer received a grant of 10,000 stock options to purchase common stock. The grant is compensation for his service on the Board of Directors.

What is the exercise price of the new stock options granted to the Sonoma Pharmaceuticals (SNOA) director?

The stock options granted to director Philippe Weigerstorfer have an exercise price of $1.2600 per share. This price is the cost per share he must pay to exercise the options.

How and when do the Sonoma Pharmaceuticals (SNOA) options granted to Philippe Weigerstorfer vest?

The options vest in three equal installments, one third each on July 9, 2027, July 9, 2028, and July 9, 2029, or upon a change of control of Sonoma Pharmaceuticals.

What is the expiration date of the Sonoma Pharmaceuticals (SNOA) options granted to the director?

The stock options granted to director Philippe Weigerstorfer expire on July 9, 2036. After this date, any unexercised options from this grant will no longer be exercisable.

How many Sonoma Pharmaceuticals (SNOA) stock options does Philippe Weigerstorfer hold after this grant?

After this grant, director Philippe Weigerstorfer holds a total of 30,001 stock options directly. This figure represents his stock option holdings following the reported transaction.

Was the Sonoma Pharmaceuticals (SNOA) director’s Form 4 transaction a market buy or sell of shares?

No. The Form 4 reports a grant/award acquisition of stock options, not an open-market buy or sell. It reflects equity compensation rather than trading activity in Sonoma Pharmaceuticals shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/09/2026 - 08:48 PM Accepted by SEC EDGAR 07/09/2026 - 08:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weigerstorfer Philippe

(Last) (First) (Middle)

C/O SONOMA PHARMACEUTICALS, INC.

5445 CONESTOGA COURT, SUITE 150

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sonoma Pharmaceuticals, Inc. [ SNOA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$1.26	07/09/2026		A		10,000		(1)	07/09/2036	Common Stock	10,000	(2)	30,001	D

Explanation of Responses:

1. The options vest one third each on 7/9/2027, 7/9/2028 and 7/9/2029, or upon change of control.

2. The options were awarded and granted to Mr. Weigerstorfer for services performed on the Board of Directors.

	/s/ Amy Trombly as attorney-in-fact	07/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)